For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Interferon Beta-1a | Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks | None | None | 1 | 62 | 44 | 62 | View |
| Placebo | Placebo IM injection twice weekly for 12 weeks | None | None | 3 | 61 | 20 | 61 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Upper Respiratory Tract Infection | None | Infections and infestations | MedDRA 12.1 | View |
| Anaemia | None | Blood and lymphatic system disorders | MedDRA 12.1 | View |
| Headache | None | Nervous system disorders | MedDRA 12.1 | View |
| Hypertension | None | Vascular disorders | MedDRA 12.1 | View |
| Colitis Ulcerative | None | Gastrointestinal disorders | MedDRA 12.1 | View |
| Myalgia | None | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | View |
| Influenza Like Illness | None | General disorders | MedDRA 12.1 | View |
| Pyrexia | None | General disorders | MedDRA 12.1 | View |
| Malaise | None | General disorders | MedDRA 12.1 | View |